Only back in this stock a few days ago, but this is exactly what...

Only back in this stock a few days ago, but this is exactly what you want to hear for this type of play:

- Their treatment is showing better results than any other indication out there

- No other major pharma has anything comparable in the pipeline (at the moment)

- The tech is patented

- This is not a one indication company, but now working on multiple diseases. Patents also issued for those.

- The DMD market in general desperately needs a treatment like that of ANP; puts the company in a strong position towards the authorities.

- Should EMA provide favorable feedback shortly, then we would also have the first major validation.

The stock movement is the usual "non-reflection" of reality, very common at these stages. The fundamentals are key today, share price will follow.

Management now have all the cards in their hands to turn this medical success into a financial success.